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Abstract
Background: There are increased numbers of activated lymphocytes in the lungs of chronic obstructive pulmonary
disease (COPD) patients. The clinical benefits of corticosteroids in COPD patients are limited. Our hypothesis is that
lymphocytes play a role in this corticosteroid insensitivity.
Objectives: To investigate the effects of the corticosteroid dexamethasone on lung lymphocyte cytokine
production from patients with COPD compared to controls.
Methods: Cultured airway lymphocytes obtained by bronchoscopy from healthy non-smokers (HNS), smokers (S)
and COPD patients were stimulated with phytohaemagglutinin (PHA) & phorbol myristate acetate (PMA), +/-
dexamethasone. Supernatants were assayed for interleukin (IL)-2 and interferon (IFN)g. Immunofluoresence was
used to analyse changes in CD8 glucocorticoid receptor (GRa and GRb) expression.
Results: The inhibition of PHA/PMA stimulated IFNg production by dexamethasone was reduced in COPD patients
compared to HNS (p < 0.05 at concentrations from 0.1-1 μM). There was also a significant reduction (p < 0.05) in
the mean inhibitory effect at 1 μM in COPD patients (54.1%) compared to smokers (72.1%), and in smokers
compared to HNS (85.5%). There was a numerically reduced effect of dexamethasone on IL-2 production that did
not reach statistical significance. There was no difference in GRa and GRb expression in follicular CD8 cells
between COPD patients (50.9% and 30.4% respectively) and smokers (52.9% and 29.7% respectively).
Conclusions: IFNg production from COPD airway lymphocytes is corticosteroid insensitive. This phenomenon may
be important in the poor clinical response often observed with corticosteroids.
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Background
Chronic obstructive pulmonary disease (COPD) is a pro-
gressive inflammatory airway disease. There are
increased numbers of lymphocytes, particularly CD8
cells, in the lungs of COPD patients leading to the sug-
gestion that COPD has an autoimmune component
[1-3]. CD8 cells are increased in the airway lumen, sub-
epithelium and parenchyma and their numbers increase
proportionate to disease severity [1]. T lymphocytes
from the airways of COPD patients produce pro-
inflammatory cytokines, with evidence of both Th1 and
Th2 cytokine production [4-8]. Furthermore, there is an
increase in organised lymphoid structures called follicles
within the lung parenchyma and associated with the
bronchial tree [9]. These follicles may function as anti-
gen presenting sites, further supporting the hypothesis
that COPD has an autoimmune component [10].
Corticosteroids are the most widely used anti-inflam-
matory drug in COPD patients. Corticosteroids bind to
the cytoplasmic glucocorticoid receptor (GR), forming a
complex that can suppress inflammatory gene transcrip-
tion [11]. However, the clinical benefits of corticosteroid
therapy in COPD are limited [12-14]. Using peripheral
blood derived lymphocytes, it has been demonstrated
that corticosteroids have reduced effects on phytohae-
magglutinin (PHA)-induced lymphoproliferative
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any medium, provided the original work is properly cited.responses in patients with rheumatoid arthritis, ulcera-
tive colitis and corticosteroid resistant asthma [15-18].
Our hypothesis was that COPD airway T lymphocytes
also have reduced sensitivity to the effects of
corticosteroids.
We report an investigation of the corticosteroid sensi-
tivity of airway T lymphocytes from COPD patients
compared to controls. The effect of dexamethasone on
bronchoalveolar lavage (BAL) T lymphocyte cytokine
production was investigated. In order to establish
whether altered GR expression plays a role in corticos-
teroid sensitivity in lymphocytes; GR expression was
quantified in CD8 cells of COPD patients and smoking
controls.
Methods
Study subjects
14 COPD patients, 10 smokers with normal lung func-
tion and 10 healthy non smokers (HNS) were recruited
(demographics shown in Table 1). Some of these
patients were recruited specifically to undergo a
bronchoscopy for research purposes (6 COPD patients,
3 smokers and 7 HNS). The remaining patients were
undergoing clinical investigational bronchoscopies for
the following reasons; haemoptysis (3 COPD patients, 1
smoker, 3 HNS), unexplained shortness of breath or
weight loss (2 COPD patients, 2 smokers), and investiga-
tion of abnormal chest X-ray findings suggestive of lung
cancer (3 COPD patients and 4 smokers). Subjects with
any other pulmonary conditions including history of
asthma were excluded. For immunofluorescent analysis,
10 COPD patients and 11 smokers with normal lung
function, undergoing surgical resection for suspected or
confirmed lung cancer were recruited. Tissue blocks
were preselected for this study based on the presence of
at least one inflammatory follicle. COPD patients were
diagnosed based on a history of smoking (> 10 pack
years), typical symptoms and airflow obstruction (FEV1
< 80% predicted, and FEV1/FVC ratio < 0.7) [19]. All
subjects gave written informed consent. The study was
approved by the local research ethics committee.
Cell collection
BAL was collected from the upper lobes, or a lobe not
affected by radiographic or endobronchial abnormalities:
T h eb r o n c h o s c o p ew a sw e d g e di nt h eb r o n c h u sa n da
maximum of 4 × 60 ml aliquots of pre-warmed sterile
0.9% NaCl solution were instilled into each lobe. The
aspirated fluid was stored on ice before filtration (100
μm filter, Becton Dickenson). The filtrate was centri-
fuged (400 g/10 min at 4°C) and the cell pellet resus-
pended in RPMI 1640 medium supplemented with 2
mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml
streptomycin. Viable cell counts were determined by try-
pan blue exclusion (Neubauer hemocytometer) and
adjusted to 1 × 10
6 cells/ml. Macrophages were depleted
by adherence by 90 minute incubation in a 24 well plate
at 37°C, 5% CO2. The non adherent cell count was
adjusted to 2 × 10
6 cells/ml in supplemented RPMI
1640 medium with additional 10% (vol/vol) fetal calf
serum. This cell suspension was then used for cell
culture.
Cell Culture
1×1 0
5 cells (non adherent BAL), were seeded in a 96
well plate +/- dexamethasone (1, 0.1 & 0.01 μM) for 2
hours at 37°C, 5% CO2 in 200 μl RPMI-1640 media sup-
plemented with 2 mM L-glutamine, 100 U/ml penicillin,
and 100 μg/ml streptomycin and 10% FCS (v/v). Subse-
quently lymphocytes were activated by addition of PHA
and phorbol myristate acetate (PMA), 10 μg/ml each.
Cells were further incubated for 24 hours. This time
point was chosen based on initial time course experi-
ments over 2 days in 3 smoking subjects (data not
shown). Supernatants (180 μl) were harvested by plate
centrifugation 10 mins, 400 g, 4°C and transferred to a
fresh 96 well plate for storage at -20°C prior to ELISA
analysis.
ELISA assay
Release of interleukin (IL)-2 and interferon (IFN) g was
assayed on cell culture supernatants (either undiluted or
Table 1 Subject Demographics data are expressed as
means (SD)
COPD
N=1 4
Smokers
N=1 0
HNS
N=1 0
COPD
N=1 0
IF
Smokers
N=1 1
IF
Sex (F/M) 4/10 3/7 5/5 4/6 5/6
Age (years) 66.9
(7.3)
62.4
(20.6)
39.5
(22.4)
65.2
(6.8)
66.1 (8.6)
Gold Stage (1/2/3) 0/13/1 N/A N/A 3/6/1 N/A
FEV1 (L) 1.8 (0.6) 2.0 (0.9) 3.4 (1.2) 2.01
(0.5)
2.06 (0.5)
FEV1% predicted 62 (12) 98 (19) 100 (15) 70.4
(11.5)
86.4
(19.3)
FEV1/FVC ratio 56
(13.8)
77 (5.7) 83 (6.0) 60.8
(11.1)
73.8 (7.7)
Pack year history 40.7
(26.4)
37.2
(28.5)
0 49.2
(39.7)
62.3
(29.5)
Current/Ex smoker 5/9 5/5 N/A 9/1 11/0
ICS Users 6 0 0 2 0
BAL Yield (mls) 91.0
(76.3)
115
(109)
190
(131)
N/A N/A
Total Cell Yield/ml
(× 10
6)
0.23 0.28 0.13 N/A N/A
Total Lymphocytes
(%)
6.9 6.6 7.6 N/A N/A
IF = immunofluoresence
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required) using R&D systems ELISA duosets according
to manufacturer’s instructions.
Dual-label Immunofluorescence
Tissue blocks were obtained from an area of the lung as
far distal to the tumour as possible, and processed as
described previously [20]. Lung tissues were cut into 4-
μm sections and lifted onto a polysine coated glass slide.
For heat induced epitope retrieval in 0.01 M trisodium
buffer pH 6 the lung sections were microwaved for 20
min at 800 W. A cocktail of CD8 with either GRa or
GRb primary antibodies diluted in 1.5% normal serum
(Vector Labs, Peterborough, UK) with 0.5% triton × 100
was applied overnight at 4°C. Two CD8 primary antibo-
dies were used to avoid applying a cocktail with two
antibodies requiring the same species secondary
antibody.
According to primary antibody species requirements,
CD8 and GR were detected using either Alexa 568 con-
jugated goat anti-rabbit immunoglobulin IgG (1:200,
Invitrogen, Paisley, UK) and Alexa 488 conjugated goat
anti-mouse immunoglobulin IgG secondary antibodies
(1:200, Invitrogen) respectively. Sections were counter-
stained with 4,6-diamidino-2-phenylindole (DAPI, Invi-
trogen). Omission of primary antibody from staining
protocol was used as a negative control.
Image Analysis
The number of CD8
+GRa
+ and CD8
+GRb
+ cells within
inflammatory follicles were calculated and presented as
a percentage of the CD8 population. Digital micrographs
were obtained using a Nikon Eclipse 80i microscope
(Nikon UK Ltd, Surrey, UK) equipped with a QImaging
digital camera (Media Cybernetics, Marlow UK) and
ImagePro Plus 5.1 software (Media Cybernetics).
Data analysis & Statistics
IL-2 and IFNg data were not normally distributed, and
so comparisons between groups were performed using a
non-parametric ANOVA. If the ANOVA was significant
(p < 0.05), then subsequent Mann Whitney U tests were
performed for pairwise comparisons. Data for the per-
centage inhibition by dexamethasone were parametric.
Paired t-tests were used to compare the effects of dexa-
methasone to PHA/PMA alone. Between group compar-
isons were performed by ANOVA. If the ANOVA was
significant (p < 0.05), then subsequent two way compar-
isons were performed using an unpaired t-test. Immu-
nofluorescence data were normally distributed;
comparisons between groups were performed using
unpaired t-tests. All analysis was carried out using
GraphPad Prism version 5 (GraphPad Software, Inc.,
San Diego, CA, USA).
Results
The cell yields/ml of recover e dB A Lf l u i dw e r en u m e r i -
cally greater in COPD patients and smokers compared to
HNS although this did not reach statistical significance
(p = 0.2) (see Table 1). There was no difference between
groups in the proportion of lymphocytes present.
Cytokine Production
Figure 1 & Table 2 show that unstimulated IFNg levels
and IL-2 levels were not significantly different between
subject groups (ANOVA p = 0.6 and 0.9 respectively).
PHA and PMA stimulation for2 4h o u r ss i g n i f i c a n t l y
increased the secretion of both IFNg and IL-2 in all 3
subject groups (p < 0.001 for all comparisons of unsti-
mulated vs stimulated levels). There was no statistical
difference in stimulated IL-2 levels between groups
(ANOVA p = 0.2). Stimulated IFNg levels were different
between groups (ANOVA p = 0.04), as there were lower
levels in HNS compared to smokers (Mann Whitney
Unpaired t test p = 0.04). There was also significantly
lower IFNg levels in COPD compared to HNS and smo-
kers (Mann Whitney U test p = 0.04).
Dexamethasone effects
Dexamethasone at all concentrations (0.01 - 1 μM)
inhibited stimulated IFNg production in all 3 subject
groups; the absolute cytokine levels with and without
dexamethasone are shown in Figure 1. As the PHA/
PMA stimulated IFNg levels were different between sub-
ject groups, the effect of dexamethasone was normalised
to the PHA/PMA levels without dexamethasone and
shown in Figure 2 as percentage inhibition. There was a
significant difference between groups for the effect of
dexamethasone on IFNg production at 1 μMa n d0 . 1
μM (ANOVA p < 0.05 for between group comparisons),
with the difference between groups not quite reaching
significance at 0.01 μM. The highest concentration of
dexamethasone (1 μM) only achieved a mean inhibition
of 54.1% of IFNg production in COPD subjects. Subse-
quent two way comparisons showed that the inhibition
of IFNg was significantly less in COPD patients com-
pared to HNS at 1 μM( U n p a i r e dtt e s tp =0 . 0 0 1 )a n d
0.1 μM (Unpaired t test p =0 . 0 0 5 ) .A t1μMt h e r ew e r e
also significant differences between COPD patients and
smokers (Unpaired t test p = 0.05), and between HNS
and smokers (Unpaired test t p = 0.05).
Dexamethasone at all concentrations (0.01-1 μM)
inhibited stimulated IL-2 production in all 3 subject
groups. There was less inhibition of IL-2 production in
COPD patients at all 3 concentrations, but these numer-
ical differences between groups did not reach statistical
significance (p > 0.05).
Within the COPD group, dexamethasone had similar
effects on current and ex smokers for both IL-2 and
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centration) (data not shown).
GR expression in follicles
There were no significant differences between the per-
centage of follicular CD8 cells that expressed either
GRa or GRb between COPD patients (means 50.9% and
30.4% respectively) and controls (mean 52.9% and 29.7%
respectively), p = 0.8 and 0.9 respectively; see Figure 3
for individual data and representative images.
Discussion
We show that the sensitivity of airway lymphocytes to
corticosteroids is reduced in COPD patients. Our results
implicate these cells as important players in the clinical
phenomenon of corticosteroid resistance in COPD.
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Figure 1 PHA/PMA induced IFNg (A) and IL-2 (B) release (pg/ml) from cultured BAL lymphocytes from healthy non-smokers (HNS) (n =
10 light bars), healthy smokers (S) (n = 10 mid grey bars) and COPD patients (n = 14 dark grey bars). Cells were pre- treated for 2 hours
with dexamethasone (0.01 - 1 μM) prior to 24 hours T cell stimulation with PHA/PMA (P/P) 10 μg/ml each. Data is presented as median (range).
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Page 4 of 9IFNg plays a key role in Th1 type inflammation and
cell mediated cytotoxicity (reviewed [21]). We show that
corticosteroids have a reduced inhibitory effect on IFNg
production in COPD patients. The clearest difference in
corticosteroid sensitivity observed was between COPD
patients and HNS, although there was also evidence of
differences between COPD patients and smokers, and
between smokers and HNS at the highest dexametha-
sone concentration (1 μM). These data suggest that
smoking itself reduces T lymphocyte corticosteroid sen-
sitivity, and that the development of COPD further
reduces corticosteroid sensitivity.
IL-2 is an integral cytokine for T lymphocyte prolif-
eration [22]. There were numerical trends suggesting a
r e d u c t i o ni nt h ei n h i b i t o r yeffect of dexamethasone on
IL-2 production in COPD patients compared to con-
trols, but these did not reach statistical significance.
Table 2 Basal and stimulated cytokine release from
healthy non smokers (HNS), smokers & COPD.
IFNg release
(pg/ml)
IL-2 release
(pg/ml)
BASAL
(A)
HNS 9.8 (3.9-651) 14.5 (6.2-39.8)
Smokers 16.3 (0-75.1) 20.6 (0-453.6)
COPD 17.3 (0-83) 29.6 (0-102.8)
P value 0.6 0.9
PHA/PMA
(B)
HNS 519 (239.4-3062) 557.6 (39.6-1228)
Smokers 1881 (87.1-19217) 954.9 (112.7-2612)
COPD 284.6 (27.6-15992) 474.2 (28.9-5011)
P value 0.04 0.2
Data are expressed as median (range).
ANOVAs for basal (A) and stimulated (B) between group comparisons are
shown beneath each column
Figure 2 Reduction of PHA/PMA induced IFNg (A) and IL-2 (B) release was converted from pg/ml into percent inhibition. Healthy non-
smokers (HNS) (n = 10 light bars), healthy smokers (S) (n = 10 mid grey bars) and COPD patients (n = 14 dark grey bars). Data are expressed as
mean (± SD). P-values from ANOVAs for between group comparisons are shown.
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between T lymphocyte cytokines, with IFNg showing
more corticosteroid resistance in COPD patients com-
pared to IL-2. The molecular mechanisms for such a
difference have not been explored. The ability of corti-
costeroids to regulate the activity of transcription factors
such as nuclear factor of activated T-lymphocytes
(NFAT), activator protein 1 (AP-1), nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-B)
and activating transcription factor (ATF) may vary
between the promoter regions of the IL-2 and IFNg
genes, and may be further altered by changes such as
c h r o m a t i nm o d u l a t i o nt h a tm a yo c c u ri nr e s p o n s et o
oxidative stress and inflammation in COPD [23].
Corticosteroid insensitivity has been observed in per-
ipheral blood lymphocytes of corticosteroid resistant
patients with asthma, ulcerative colitis and rheumatoid
arthritis, as well as renal transplant recipients [14-16,24].
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Figure 3 Representative images for the dual immunofluorescence detection of CD8
+GRa
+ and CD8
+GRb
+ T- cells within human lung
tissue from (A&B) a COPD subject and (C&D) a smoking control subject. (A&C) CD8
+ cells were identified using an Alexa-488 conjugated
goat anti-rabbit secondary antibody (Green stain) and GRa
+ cells were detected using an Alexa-568 conjugated goat anti-mouse secondary
antibody (Red stain). (B&D) CD8
+ cells were identified using an Alexa-568 conjugated goat anti-mouse secondary antibody (Red stain) and GRb
+
cells were detected using an Alexa-488 conjugated goat anti-rabbit secondary antibody (Green stain). Cell nuclei were counterstained with 4’,6 -
diamidino-2-phenylindole (DAPI, blue stain). Magnification × 200. (E&F) Analysis of the number of CD8+ cells that were also positive for GRa and
GRb, within COPD (n = 10) and smoking control (n = 11) follicles. Data presented as mean + SD.
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induce corticosteroid insensitivity in murine T lympho-
cytes [25] as well as in PBMCs from healthy volunteers
by reducing GR binding affinity [26]. IL-2 mRNA levels
are increased in the BAL of steroid resistant patients
with asthma [27]. We speculate that IL-2 may play a
role in the corticosteroid insensitivity observed in the
current study.
IFNg predisposes the airway microenvironment to a
proinflammatory Th1 environment and plays a key role
in host defence against viruses [28]. Pulmonary IFNg
levels are increased in COPD patients [29-31], and it
has also been reported that COPD severity is related to
the degree of IFNg production by CD8 cells [32]. Viral
infections can increase IFNg levels in COPD patients
[33,34].
Our data suggests that that lymphocyte IFNg produc-
tion is corticosteroid resistant in COPD patients. This
raises the possibility that virally induced IFNg produc-
tion in COPD patients is poorly suppressed by corticos-
teroids; the poor response of viral exacerbations of
COPD to corticosteroids is an observation frequently
noted by clinicians treating exacerbations.
The number of T lymphocytes in the lungs increases
with the severity of COPD [1,35,36]. These T lympho-
cytes display an increased Th1 response [4,7]. Results in
this study suggest that IFNg c o u l dp l a yac e n t r a lr o l ei n
persistent Th1 inflammation in COPD, as it responds
poorly to corticosteroids. Novel therapies that specifi-
cally target IFNg activity may reduce Th1 inflammation
in COPD, such as targeting of the janus kinase (JAK)-
signal transducer and activator of transcription (STAT)
pathway [37].
Our data suggests that IFNg release from COPD lym-
phocytes is reduced compared to controls. This finding
differs from studies that show increased IFNg produc-
tion from COPD lymphocytes [4,7], and increased levels
of IFNg in the airways of COPD patients compared to
controls [29-31]. We observed a similar trend for lower
IL-2 production in COPD, although this did not reach
statistical significance. Reduced cytokine production by
alveolar macrophages has been reported from smokers
and patients with COPD [38-40] which is thought to be
due to a “blunting” effect of cigarette smoke on cell sig-
nalling mechanisms such as p38 mitogen activated pro-
tein kinase and NFB [40]. It is possible that a similar
effect is also present in COPD lymphocytes. However,
as this phenomenon has not been observed in previous
studies of COPD lymphocytes [35,36], it is also possible
that our findings for both IFNg and IL-2 are due to ran-
dom individual variation in a limited sample size rather
than a true biological effect.
Corticosteroids bind to GR forming a complex that
translocates to the nucleus to interfere with the binding
of transcription factors such as NF-B to the promoter
regions of inflammatory genes [11]. A range of molecu-
lar mechanisms have been investigated as possible expla-
nations for corticosteroid insensitivity, including the
overexpression of the dominant negative splice variant
isoform GRb which is associated with corticosteroid
insensitivity in different cell types [41-43] and is
reported to be increased in steroid resistant patients
with asthma and ulcerative colitis [44-47]. Studies in
COPD patients have focused on the role of histone dea-
cetylases which are recruited by ligand activated GR to
reverse the unwinding of chromatin that occurs during
inflammatory gene transcription; the activity of histone
deacetylases has been reported to be reduced in COPD
patients, leading to decreased corticosteroid activity [23].
It has been reported that GRa and b expression is
reduced in the peripheral lungs of COPD patients com-
pared to controls [48]. However, we observed no differ-
ence in either GRa or GRb expression by CD8 cells
within lymphoid follicles in COPD compared to smok-
ing controls. This suggests that altered GR expression
level is not the mechanism responsible for the corticos-
teroid insensitivity observed in the current study. We
did not have access to sufficient samples from non-
smoking controls for this analysis, as the majority of
lung cancer patients are current or ex-smokers. Corti-
costeroid insensitivity is probably both a cell type and
disease specific phenomenon, and further studies should
address the mechanisms responsible for the corticoster-
oid resistance in COPD airway lymphocytes observed in
the current study.
Conclusions
In conclusion, we have shown that T lymphocytes from
the airways COPD patients display corticosteroid insen-
sitivity. The mechanisms responsible for our findings
require further study. Airway lymphocytes may play a
key role in the corticosteroid insensitivity observed in
COPD patients.
Abbreviations
AP-1: Activator protein 1; ATF: Activating transcription factor; BAL:
Bronchoalveolar lavage; COPD: Chronic Obstructive Pulmonary Disease; DAPI:
4,6-diamidino-2-phenylindole; FCS: Fetal calf serum; FEV1: Forced expired
volume in 1 second; FVC: Forced vital capacity; GR: Glucocorticoid receptor;
HNS: Healthy non smoker; IFN: Interferon; IL: Interleukin; NFAT: Nuclear factor
of activated T-cells; NF-κB; Nuclear factor kappa-light-chain-enhancer of
activated B cells; PHA: Phytohaemagglutinin; PMA: Phorbol myristate acetate;
S: Smokers.
Author details
1University of Manchester, Manchester Academic Health Science Centre,
NIHR Translational Research Facility, University Hospital of South Manchester
Foundation Trust, Southmoor Road, Manchester, UK M23 9LT.
2School of
Medicine, University of Manchester, Oxford Road, Manchester, UK M13 9PT.
3Centre for Parasitology and Disease, School of Environment and Life
Sciences, University of Salford, Salford, UK M5 4WT.
Kaur et al. Respiratory Research 2012, 13:20
http://respiratory-research.com/content/13/1/20
Page 7 of 9Authors’ contributions
MK: carried out main body of lab work, data analysis and manuscript
composition. LS: carried out main body of lab work and manuscript
composition. PC: involved in subject recruitment, research bronchscopies,
contribution to lab work and data analysis. SG: subject recruitment, research
bronchsocopies and data analysis. JP: carried out the immunofluoresence
work and contributed to the manuscript. DR: involved in study design, data
analysis and manuscript composition, DS: involved in study design, data
analysis and senior contribution to manuscript composition.
Competing interests
Manminder Kaur, Lucy Smyth, Paul Cadden, Seamus Grundy and Jonathan
Plumb, have no competing interest to declare. Dave Singh and David Ray
are supported by research grants as outlined in their personal declarations.
Received: 21 February 2011 Accepted: 14 March 2012
Published: 14 March 2012
References
1. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L,
Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Pare PD: The nature of
small-airway obstruction in COPD. N Engl J Med 2004, 24:2645-2653.
2. Agusti A, MacNee W, Donaldson K, Cosio M: Hypothesis: Does COPD have
an autoimmune component? Thorax 2003, 58:832-834.
3. Lee SH, Goswami S, Grudo A, Song LZ, Bandi V, Goodnight-White S,
Green L, Hacken-Bitar J, Huh J, Bakeen F, Coxson HO, Cogswell S, Storness-
Bliss C, Corry DB, Kheradmand F: Antielastin autoimmunity in tobacco
smoking-induced emphysema. Nat Med 2007, 5:567-569.
4. Hodge G, Nairn J, Holmes M, Reynolds PN, Hodge S: Increased intracellular
T helper 1 proinflammatory cytokine production in peripheral blood,
bronchoalveolar lavage and intraepithelial T cells of COPD subjects. Clin
Exp Immunol 2007, 150:22-29.
5. Majori M, Corradi M, Caminati A, Cacciani G, Bertacco S, Pesci A:
Predominant TH1 cytokine pattern in peripheral blood from subjects
with COPD. J Allergy Clin Immunol 1999, 103:458-462.
6. Barczyk A, Pierzchała W, Kon OM, Cosio B, Adcock IM, Barnes PJ: Cytokine
production by bronchoalveolar lavage T lymphocytes in chronic
obstructive pulmonary disease. J Allergy Clin Immunol 2006,
117:1484-1492.
7. Barceló B, Pons J, Fuster A, Sauleda J, Noguera A, Ferrer JM, Agusti AG:
Intracellular cytokine profile of T lymphocytes in patients with chronic
obstructive pulmonary disease. Clin Exp Immunol 2006, 145:474-479.
8. Di Stefano A, Caramori G, Capelli A, Gnemmi I, Ricciardolo FL, Oates T,
Donner CF, Chung KF, Barnes PJ, Adcock IM: STAT4 activation in smokers
and patients with chronic obstructive pulmonary disease. Eur Respir J
2004, 24:78-855.
9. Van der Strate B, Postma D, Brandsma C, Melget B, Luinge M, Geerlings M,
Hylkema M, van der Berg A, Timmens W, Kerstjens H: Cigarette smoke
induced emphysema: a role for the B cell? Am J Respir Crit Care Med 2006,
173:751-758.
10. Lambers C, Hacker S, Posch M, Hoetzenecker K, Pollreisz A, Lichtenauer M,
Klepetko W, Ankersmit H: T cell senescence and contraction of T cell
repertoire diversity in patients with chronic obstructive pulmonary
disease. Clin Exp Immunol 2009, 155:466-475.
11. Leung DY, Bloom JW: Update on glucocorticoid action and resistance. J
Allergy Clin Immunol 2003, 111:3-22.
12. Loppow D, Schleiss MB, Kanniess F, Taube C, Jorres RA, Magnussen H: In
patients with chronic bronchitis a four week trial with inhaled steroids
does not attenuate airway inflammation. Respir Med 2001, 95:115-121.
13. Culpitt SV, Maziak W, Loukidis S, Nightingale JA, Matthews JL, Barnes PJ:
Effect of high dose inhaled steroid on cells, cytokines and proteases in
induced sputum in Chronic Obstructive Pulmonary Disease. Am J Respir
Crit Care Med 1999, 160:1635-1639.
14. Soriano JB, Sin DD, Zhang X, Camp PG, Anderson JA, Anthonisen NR,
Buist AS, Burge PS, Calverly OM, Connet JE, Petersson S, Postma DS,
Szafranski W, Vestbo J: A pooled analysis of FEV1 decline in COPD
patients randomized to inhaled corticosteroids or placebo. Chest 2007,
131:682-689.
15. Howe LJ, Stanford MR, Edelsten C, Graham EM: The efficacy of systemic
corticosteroids in sight-threatening retinal vasculitis. Eye 1994, 8:443-447.
16. Corrigan CJ, Brown PH, Barnes NC, Szefler SJ, Tasi JJ, Frew AJ, Kay AB:
Glucocorticoid resistance in chronic asthma: glucocorticoid
pharmacokinetics, glucocorticoid receptor characteristics, and inhibition
of peripheral blood T cell proliferation by glucocorticoids in vitro. Am
Rev Respir 1991, 144:1016-1025.
17. Hearing SD, Norman M, Probert CS, Haslam N, Dayan CM: Predicting
therapeutic outcome in severe ulcerative colitis by measuring in vitro
steroid sensitivity of proliferating peripheral blood lymphocytes. Gut
1999, 45:382-388.
18. Kirkham BW, Corkill MM, Davison SC, Panayi GS: Response to
glucocorticoid treatment in rheumatoid arthritis: in vitro cell mediated
immune assay predicts in vivo responses. J Rheumatol 1991, 18:821-825.
19. Global initiative for chronic Obstructive Lung Disease. [http://www.
goldCOPD.com].
20. Plumb J, Smyth LJ, Adams HR, Vestbo J, Bentley A, Singh SD: Increased T
regulatory cells within lymphocyte follicles in moderate COPD. Eur Respir
J 2009, 34:89-94.
21. Schroder K, Hertzog PJ, Ravasi T, Hume DA: Interferon-gamma: an
overview of signals, mechanisms and functions. J Leukoc Biol 2004,
75:163-189.
22. Smith KA: Interleukin 2: inception, impact & implications. Science 1988,
240:1169-1176.
23. Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, Barczyk A, Hayashi S,
Adcock IM, Hogg JC, Barnes PJ: Decreased histone deacetylase activity in
COPD. New Engl J Med 2005, 352:1967-1976.
24. Langhoff E, Jakobsen BK, Ryder LP, Svejgard A, Thaysen JH: Recipient
lymphocyte sensitivity to methylprednisolone affects cadaver kidney
graft survival. Lancet 1986, 327:1296-1297.
25. Goleva E, Kisich KO, Leung DY: A role for STAT5 in the pathogenesis of IL-
2-induced glucocorticoid resistance. J Immunol 2002, 169:5934-5940.
26. Kam JC, Szefler SJ, Surs W, Sher ER, Leung DY: Combination IL-2 and IL-4
reduces glucocorticoid receptor-binding affinity and T cell response to
glucocorticoids. J Immunol 1993, 151:3460-3466.
27. Leung DY, Martin RJ, Szefler SJ, Sher ER, Ying S, Kay AB, Hamid Q:
Dysregulation of interleukin 4, interleukin 5, and interferon-γ gene
expression in steroid-resistant asthma. J Exp Med 1995, 181:33-40.
28. Schoenborn JR, Wilson CB: Regulation of interferon-gamma during innate
and adaptive immune responses. Adv Immunol 2007, 96:41-101.
29. Hens G, Vanaudenaerde BM, Bullens DM, Piessens M, Decramer M,
Dupont LJ, Ceuppens JL, Hellings PW: Sinonasal pathology in nonallergic
asthma and COPD: ‘united airway disease’ beyond the scope of allergy.
Allergy 2008, 63:261-267.
30. Panzner P, Lafitte JJ, Tsicopoulos A, Hamid Q, Tulic MK: Marked up-
regulation of T lymphocytes and expression of interleukin-9 in bronchial
biopsies from patients with chronic bronchitis with obstruction. Chest
2003, 124:1909-1915.
31. Reeves EP, Williamson M, Byrne B, Bergin DA, Smith SG, Greally P,
O’Kennedy R, O’Neill SJ, McElvaney NG: IL-8 dictates glycosaminoglycan
binding and stability of IL-18 in cystic fibrosis. J Immunol 2010,
184:1642-1652.
32. Zhu X, Gadgil AS, Givelber R, George MP, Stoner MW, Sciurba FC,
Duncan SR: Peripheral T cell functions correlate with the severity of
chronic obstructive pulmonary disease. J Immunol 2009, 182:3270-3277.
33. Singh M, Lee SH, Porter P, Xu C, Ohno A, Atmar RL, Greenberg SB, Bandi V,
Gern J, Amineva S, Aminev A, Skern T, Smithwock P, Perusich S, Barrow N,
Roberts L, Corry DB, Kheradmand F: Human rhinovirus proteinase 2A
induces TH1 and TH2 immunity in patients with chronic obstructive
pulmonary disease. J Allergy Clin Immunol 2010, 125:1369-1378.
34. Makris D, Lazarou S, Alexandrakis M, Kourelis TV, Tzanakis N, Kyriakou D,
Gourgoulianis KI: Tc2 response at the onset of COPD exacerbations. Chest
2008, 134:483-488.
35. Saetta M, Stefano AD, Turato G, Facchini FM, Corbino L, Mapp CE,
Maestrelli P, Ciaccia A, Fabbri L: CD8 T-Lymphocytes in peripheral airways
of smokers with chronic obstructive pulmonary disease. Am J Respir Cirt
Care Med 1998, 157:822-826.
36. Saetta M, Baraldo S, Corbino L, Turato G, Braccioni F, Rea F, Cavallesco G,
Tropeano G, Mapp CE, Maestrelli P, Ciaccia A, Fabbri LM: CD8+ve cells in
the lungs of smokers with chronic obstructive pulmonary disease. Am J
Respir Cirt Care Med 1999, 160:711-717.
37. Clarke D, Clifford RL, Jindarat S, Proud D, Pang I, Belvsi M, Knox AJ: TNFα
and IFNγ synergistically enhance transcriptional activation of CXCL10 in
Kaur et al. Respiratory Research 2012, 13:20
http://respiratory-research.com/content/13/1/20
Page 8 of 9human airway smooth muscle cells via STAT-1, NF-κB, and the
transcriptional coactivator CREB-binding protein. J Biol Chem 2010,
285:29101-29110.
38. Armstrong J, Sargent C, Singh D: Glucocorticoid sensitivity of
lipopolysaccharide-stimulated chronic obstructive pulmonary disease
alveolar macrophages. Clin Exp Immunol 2009, 158:74-83.
39. Kent LM, Fox SM, Farrow SN, Singh D: The effects of dexamethasone on
cigarette smoke induced gene expression in COPD macrophages. Int
Immunopharmacol 2010, 10:57-64.
40. Chen H, Cowan MJ, Hasday JD, Vogel SN, Medvedev AE: Tobacco smoking
inhibits expression of proinflammatory cytokines and activation of IL-1R-
associated kinase, p38, and NF-kappaB in alveolar macrophages
stimulated with TLR2 and TLR4 agonists. J Immunol 2007, 179:6097-6106.
41. Neeck G, Klüter A, Dotzlaw H, Eggert M: Involvement of the
Glucocorticoid Receptor in the pathogenesis of rheumatoid arthritis. Ann
N Y Acad Sci 2002, 966:491-495.
42. Pujols L, Mullol J, Picado C: Alpha and beta glucocorticoid receptors:
relevance in airway diseases. Curr Allergy Asthma Rep 2007, 7:93-99.
43. Pujols L, Mullol J, Torrego A, Picado C: Glucocorticoid receptors in human
airways. Allergy 2004, 59:1042-1052.
44. Kraft M, Hamid Q, Chrousos GP, Martin RJ, Leung DY: Decreased steroid
responsiveness at night in nocturnal asthma is the macrophage
responsible? Am J Respir Crit Care Med 2001, 163:1219-1225.
45. Adcock IM, Lane SJ, Brown CR, Lee TH, Barnes PJ: Abnormal glucocorticoid
receptor-activator protein 1 interaction in steroid-resistant asthma. J Exp
Med 1995, 182:1951-1958.
46. Sousa AR, Lane SJ, Cidlowski JA, Staynov DZ, Lee TH: Glucocorticoid
resistance in asthma is associated with elevated in vivo expression of
the glucocorticoid receptor β-isoform. J Allergy Clin Immunol 2000,
105:943-950.
47. Honda M, Orii F, Ayabe T, Imai S, Ashida T, Obara T: Kohgoy: Expression of
glucocorticoid receptor in lymphocytes of patients with glucocorticoid-
resistant ulcerative colitis. Gastroenterology 2000, 118:859-866.
48. Marwick JA, Gaetano C, Stevenson CS, Casolari P, Jazrawi E, Barnes PJ, Ito K,
Adcock IM, Kirkham PA, Papi A: Inhibition of PI3Kd restores glucocorticoid
function in smoking-induced airway inflammation in mice. Am J Respir
Crit Care Med 2009, 179:542-548.
doi:10.1186/1465-9921-13-20
Cite this article as: Kaur et al.: T lymphocyte insensitivity to
corticosteroids in chronic obstructive pulmonary disease. Respiratory
Research 2012 13:20.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kaur et al. Respiratory Research 2012, 13:20
http://respiratory-research.com/content/13/1/20
Page 9 of 9